Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
No Surprises from Vertex (VRTX) But Piper Jaffray Moves Price Target Down to $143
January 28, 2016 7:25 AM ESTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating but lowered his price target on Vertex (NASDAQ: VRTX) to $143.00 (from $180.00) following results which offered no surprises.
Tenthoff commented, "As pre-announced, >4,500 patients began ORKAMBI in the U.S. resulting in sales of $220 million in 4Q:15;... More
Vertex Pharma (VRTX) Reports In-Line Q4 EPS
January 27, 2016 4:03 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $0.17, in-line with the analyst estimate of $0.17. Revenue for the quarter came in at $417.94 million versus the consensus estimate of $406.3 million.
"Entering 2016, Vertex is in a strong financial position to support continued investment in our business to create future medicines for serious diseases and value for our shareholders," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "We look forward... More
